Gwo Xi Stem Cell Applied Technology Co. , Ltd (TPEX:6704)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
22.05
+0.05 (0.23%)
Apr 29, 2026, 1:58 PM CST
0.46%
Market Cap 2.12B
Revenue (ttm) 187.02M
Net Income (ttm) -80.52M
Shares Out 95.95M
EPS (ttm) -0.84
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 78,869
Average Volume 207,327
Open 22.05
Previous Close 22.00
Day's Range 21.30 - 22.05
52-Week Range 20.55 - 33.65
Beta 0.15
RSI 45.29
Earnings Date Apr 29, 2026

About TPEX:6704

Gwo Xi Stem Cell Applied Technology Co. , Ltd develops stem cell technology for patients with unmet medical needs. Its products under development include GXHPC1, an autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of liver cirrhosis; and GXNPC1, an autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of chronic stroke. The company is also developing GXCPC1, an allogeneic adipose-derived stem cells therapy in phase I/II clinical trials for use in the tr... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2011
Employees 55
Stock Exchange Taipei Exchange
Ticker Symbol 6704
Full Company Profile

Financial Performance

In 2025, TPEX:6704's revenue was 187.02 million, an increase of 10.00% compared to the previous year's 170.03 million. Losses were -80.52 million, -3.36% less than in 2024.

Financial Statements

News

There is no news available yet.